Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

Author： Ascierto Paolo Antonio   Simeone Ester   Sileni Vanna Chiarion   Vecchio Michele Del   Marchetti Paolo   Cappellini Gian Carlo Antonini   Ridolfi Ruggero   de Rosa Francesco   Cognetti Francesco   Ferraresi Virginia   Testori Alessandro   Queirolo Paola   Bernengo Maria Grazia   Guida Michele   Galli Luca   Mandalà Mario   Cimminiello Carolina   Rinaldi Gaetana   Carnevale-Schianca Fabrizio   Maio Michele  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.32, Iss.4, 2014-05, pp. : 144-149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

By Wilgenhof Sofie   Four Stephanie Du   Everaert Hendrik   Neyns Bart  

Cancer Investigation, Vol. 30, Iss. 10, 2012-12 ,pp. : 712-720

Informa Healthcare

Access to resources Recommend Favorite

Systematic Review: Surgery for Patients with Metastatic Melanoma during Active Treatment with Ipilimumab

By Baker Justin J.   Stitzenberg Karyn B.   Collichio Frances A.   Meyers Michael O.   Ollila David W.  

The American Surgeon, Vol. 80, Iss. 8, 2014-08 ,pp. : 805-810

Southeastern Surgical Congress

Access to resources Recommend Favorite

Ipilimumab for advanced metastatic melanoma

By Starz Hans  

Expert Opinion on Biological Therapy, Vol. 12, Iss. 8, 2012-08 ,pp. : 981-982

Informa Healthcare

Access to resources Recommend Favorite

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1617-1619

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

By Ascierto Paolo A.   Margolin Kim  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1617-1619

Blackwell Publishing

Access to resources Recommend Favorite